Article
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Antimicrobial agents and chemotherapy - 1 Jul 2013
Xu Hong-Tao, Colby-Germinario Susan P, Asahchop Eugene L, Oliveira Maureen, McCallum Matthew, Schader Susan M, Han Yingshan, Quan Yudong, Sarafianos Stefan G, Wainberg Mark A
Abstract excerpt
Impacts of mutations at position E138 (A/G/K/Q/R/V) alone or in combination with M184I in HIV-1 reverse transcriptase (RT) were investigated. We also determined why E138K is the most prevalent nonnucleoside reverse transcriptase inhibitor mutation in patients failing rilpivirine (RPV) therapy. Recombinant RT enzymes and viruses containing each of the above-mentioned mutations were generated, and drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.